April 20, 2021 09:05 AM EDTUpdated April 23, 02:47 PM
Bioregnum
Coronavirus

A top an­a­lyst sees Pfiz­er and Mod­er­na seiz­ing a $38B prize as safe­ty frets side­line glob­al vac­cine play­ers

While the wran­gling over the rel­a­tive safe­ty of new, vi­ral­ly vec­tored Covid vac­cines from J&J and As­traZeneca ap­pears to be un­end­ing, an­a­lysts aren’t wait­ing around …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times